Literature DB >> 19335954

Polymorphisms in CCL5 promoter are associated with pulmonary tuberculosis in northern Spain.

M Sánchez-Castañón1, I C Baquero, P Sánchez-Velasco, M-C Fariñas, F Ausín, F Leyva-Cobián, J G Ocejo-Vinyals.   

Abstract

OBJECTIVE: To study whether two functional single nucleotide polymorphisms of the CC chemokine ligand 5 (CCL5) gene could affect susceptibility to pulmonary tuberculosis (TB) in a human immunodeficiency virus negative genetically homogeneous population, containing newly diagnosed patients with active disease.
DESIGN: Seventy-six patients with active pulmonary TB (PTB) and 157 healthy control subjects from Cantabria, northern Spain, were genotyped for the CCL5 -403G/A and -28C/G polymorphisms.
RESULTS: The frequency of the CCL5-403G/A and -28C/G promoter polymorphisms were significantly different between patients with active TB and control subjects. Three of the four possible haplotypes were also significantly different. The G/G-C/C diplotype was much more frequent in the healthy control group and the G/G-G/G and A/A-C/C diplotypes were more frequent in patients with PTB.
CONCLUSION: Our findings indicate that CCL5 may play a role in conferring susceptibility to active PTB. Thus, the -403G and -28C alleles, either separately or combined in the G-C haplotype and the GG/CC diplotype, may be related to protection against PTB. By contrast, the -403A and -28G alleles, the G-G or A-C haplotypes and the G/G-G/G and A/A-C/C diplotypes may confer susceptibility to PTB.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19335954

Source DB:  PubMed          Journal:  Int J Tuberc Lung Dis        ISSN: 1027-3719            Impact factor:   2.373


  11 in total

Review 1.  Innate immune gene polymorphisms in tuberculosis.

Authors:  Abul K Azad; Wolfgang Sadee; Larry S Schlesinger
Journal:  Infect Immun       Date:  2012-07-23       Impact factor: 3.441

Review 2.  Chemokines shape the immune responses to tuberculosis.

Authors:  Samantha R Slight; Shabaana A Khader
Journal:  Cytokine Growth Factor Rev       Date:  2012-11-16       Impact factor: 7.638

3.  CCL5 participates in early protection against Mycobacterium tuberculosis.

Authors:  Bridget Vesosky; Erin K Rottinghaus; Paul Stromberg; Joanne Turner; Gillian Beamer
Journal:  J Leukoc Biol       Date:  2010-04-06       Impact factor: 4.962

Review 4.  Chemokines in tuberculosis: the good, the bad and the ugly.

Authors:  Leticia Monin; Shabaana A Khader
Journal:  Semin Immunol       Date:  2014-10-22       Impact factor: 11.130

5.  Chemokine (C-C motif) ligand 5 -28C>G is significantly associated with an increased risk of tuberculosis: a meta-analysis.

Authors:  Lelin Hu; Kaixian Zhang; Lihong Yao; Junjie Wang
Journal:  Int J Clin Exp Med       Date:  2015-08-15

6.  A meta-analysis of the association between the CC chemokine ligand 5 (CCL5) -403 G>A gene polymorphism and tuberculosis susceptibility.

Authors:  M Y Areeshi; Raju K Mandal; Aditya K Panda; Shafiul Haque
Journal:  PLoS One       Date:  2013-08-28       Impact factor: 3.240

Review 7.  The association between the CC chemokine ligand 5 -28C>G gene polymorphism and tuberculosis susceptibility.

Authors:  Hongfang Lu; Jingang Wang; Baoan Gao; Shixiong Chen; Guangming Xiang; Shaojuan Yang; Yuan Gong; Li Guan
Journal:  Saudi Med J       Date:  2015-12       Impact factor: 1.484

8.  Association of chemotactic chemokine ligand 5 rs2107538 polymorphism with tuberculosis susceptibility: A meta-analysis.

Authors:  Yun-Feng Sheng; Qi Qi
Journal:  Innate Immun       Date:  2019-12-25       Impact factor: 2.680

9.  A genetic association study of CCL5 -28 C>G (rs2280788) polymorphism with risk of tuberculosis: a meta-analysis.

Authors:  Mohammed A A Alqumber; Raju K Mandal; Shafiul Haque; Aditya K Panda; Naseem Akhter; Arif Ali
Journal:  PLoS One       Date:  2013-12-23       Impact factor: 3.240

10.  Genomic Diversity of Mycobacterium tuberculosis Complex Strains in Cantabria (Spain), a Moderate TB Incidence Setting.

Authors:  Inmaculada C Pérez Del Molino Bernal; Troels Lillebaek; Mathias K Pedersen; Luis Martinez-Martinez; Dorte B Folkvardsen; Jesús Agüero; E Michael Rasmussen
Journal:  PLoS One       Date:  2016-06-17       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.